Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor
Abstract Background Prompt evaluation and treatment of acute coronary syndrome has demonstrated to reduce mortality. Although several biomarkers have been studied for risk stratification and prognostic purposes, none is recommended to guide treatment based on its prognostic value. Copeptin and hepat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2022-04-01
|
| Series: | The Egyptian Heart Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43044-022-00275-9 |
| _version_ | 1818012364088279040 |
|---|---|
| author | María-Consuelo Pintado Lara Maceda María Trascasa Ignacio Arribas Raúl De Pablo |
| author_facet | María-Consuelo Pintado Lara Maceda María Trascasa Ignacio Arribas Raúl De Pablo |
| author_sort | María-Consuelo Pintado |
| collection | DOAJ |
| description | Abstract Background Prompt evaluation and treatment of acute coronary syndrome has demonstrated to reduce mortality. Although several biomarkers have been studied for risk stratification and prognostic purposes, none is recommended to guide treatment based on its prognostic value. Copeptin and hepatocyte growth factor have been associated with poor outcome in patients with acute myocardial infarction. The aim of this study is to evaluate the early prognostic value of measurements of copeptin and hepatocyte growth factor for hospital mortality risk and 1-year-follow-up mortality, in patients with acute myocardial infarction. In our retrospective observational study, we measured hepatocyte growth factor and copeptin in blood samples collected at hospital arrival in patients with acute myocardial infarction; and follow-up them until 1-year. Results 84 patients with were included in the study, mainly male (65%) with a median age of 70.3 ± 13.56 years. Hospital mortality was 11.9%. Plasma levels of copeptin at hospital arrival were statistically significant higher in patients who died during hospital admission (145.60 pmol/L [52.21–588.50] vs. 24.79 pmol/L [10.90–84.82], p 0.01). However, we found no statistically significant association between plasma levels of hepatocyte growth factor and hospital mortality (381.05 pg/ml [189.95–736.65] vs. 355.24 pg/ml [175.55–521.76], p 0.73). 1-year follow-up mortality was 21.4%. Plasma levels of copeptin at hospital arrival were higher in those patients who died in the following year (112.28 pmol/L [25.10–418.27] vs. 23.82 pmol/L [10.96–77.30], p 0.02). In the case of HGF, we also find no association between hepatocyte growth factor plasma levels and 1 -year follow-up mortality (350.00 pg/ml [175.05–555.08] vs. 345.53 pg/ml [183.68–561.15], p 0.68). Conclusions In patients with acute myocardial infarction measurement of copeptin at hospital arrival could be a useful tool to assess the prognosis of these patients, since their elevation is associated with a higher hospital mortality and higher 1-year follow-up mortality. We have not found this association in the case of hepatocyte growth factor measurement. |
| first_indexed | 2024-04-14T06:19:10Z |
| format | Article |
| id | doaj.art-e44089703cb24fa78cb24878c537cea7 |
| institution | Directory Open Access Journal |
| issn | 2090-911X |
| language | English |
| last_indexed | 2024-04-14T06:19:10Z |
| publishDate | 2022-04-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Heart Journal |
| spelling | doaj.art-e44089703cb24fa78cb24878c537cea72022-12-22T02:08:06ZengSpringerOpenThe Egyptian Heart Journal2090-911X2022-04-017411810.1186/s43044-022-00275-9Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factorMaría-Consuelo Pintado0Lara Maceda1María Trascasa2Ignacio Arribas3Raúl De Pablo4Critical Care Unit, Hospital Universitario Príncipe de AsturiasDepartment of Biochemistry, Hospital Universitario Príncipe de Asturias, Carretera Alcalá-Meco SNCritical Care Unit, Hospital Universitario Príncipe de AsturiasDepartment of Biochemistry, Hospital Universitario Ramón y CajalUniversity of AlcaláAbstract Background Prompt evaluation and treatment of acute coronary syndrome has demonstrated to reduce mortality. Although several biomarkers have been studied for risk stratification and prognostic purposes, none is recommended to guide treatment based on its prognostic value. Copeptin and hepatocyte growth factor have been associated with poor outcome in patients with acute myocardial infarction. The aim of this study is to evaluate the early prognostic value of measurements of copeptin and hepatocyte growth factor for hospital mortality risk and 1-year-follow-up mortality, in patients with acute myocardial infarction. In our retrospective observational study, we measured hepatocyte growth factor and copeptin in blood samples collected at hospital arrival in patients with acute myocardial infarction; and follow-up them until 1-year. Results 84 patients with were included in the study, mainly male (65%) with a median age of 70.3 ± 13.56 years. Hospital mortality was 11.9%. Plasma levels of copeptin at hospital arrival were statistically significant higher in patients who died during hospital admission (145.60 pmol/L [52.21–588.50] vs. 24.79 pmol/L [10.90–84.82], p 0.01). However, we found no statistically significant association between plasma levels of hepatocyte growth factor and hospital mortality (381.05 pg/ml [189.95–736.65] vs. 355.24 pg/ml [175.55–521.76], p 0.73). 1-year follow-up mortality was 21.4%. Plasma levels of copeptin at hospital arrival were higher in those patients who died in the following year (112.28 pmol/L [25.10–418.27] vs. 23.82 pmol/L [10.96–77.30], p 0.02). In the case of HGF, we also find no association between hepatocyte growth factor plasma levels and 1 -year follow-up mortality (350.00 pg/ml [175.05–555.08] vs. 345.53 pg/ml [183.68–561.15], p 0.68). Conclusions In patients with acute myocardial infarction measurement of copeptin at hospital arrival could be a useful tool to assess the prognosis of these patients, since their elevation is associated with a higher hospital mortality and higher 1-year follow-up mortality. We have not found this association in the case of hepatocyte growth factor measurement.https://doi.org/10.1186/s43044-022-00275-9Hepatocyte growth factorCopeptinMyocardial infarctionPrognosisHospital mortalityFollow-up study |
| spellingShingle | María-Consuelo Pintado Lara Maceda María Trascasa Ignacio Arribas Raúl De Pablo Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor The Egyptian Heart Journal Hepatocyte growth factor Copeptin Myocardial infarction Prognosis Hospital mortality Follow-up study |
| title | Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
| title_full | Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
| title_fullStr | Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
| title_full_unstemmed | Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
| title_short | Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor |
| title_sort | prognostic tools at hospital arrival in acute myocardial infarction copeptin and hepatocyte growth factor |
| topic | Hepatocyte growth factor Copeptin Myocardial infarction Prognosis Hospital mortality Follow-up study |
| url | https://doi.org/10.1186/s43044-022-00275-9 |
| work_keys_str_mv | AT mariaconsuelopintado prognostictoolsathospitalarrivalinacutemyocardialinfarctioncopeptinandhepatocytegrowthfactor AT laramaceda prognostictoolsathospitalarrivalinacutemyocardialinfarctioncopeptinandhepatocytegrowthfactor AT mariatrascasa prognostictoolsathospitalarrivalinacutemyocardialinfarctioncopeptinandhepatocytegrowthfactor AT ignacioarribas prognostictoolsathospitalarrivalinacutemyocardialinfarctioncopeptinandhepatocytegrowthfactor AT rauldepablo prognostictoolsathospitalarrivalinacutemyocardialinfarctioncopeptinandhepatocytegrowthfactor |